Asthma accounts for approximately 250,000 deaths around the world annually, deaths that otherwise could be easily prevented through appropriate treatment The asthma market saw very slow growth over the past decade, as it has become saturated with relatively efficacious standard therapies, such as short-acting beta-agonists (SABAs), inhaled corticosteroids (ICSs), inhaled corticosteroids and long-acting beta-agonists (ICS/LABAs), and leukotriene modifiers, and has also been facing increasing generic competition. However, the launch of seven novel targeted biologic agents and once-daily ICS and ICS/LABA therapies delivered by the next-generation inhalers will strongly drive the market growth over the next 10 years. The biologic agents will not only reshape the market growth, but will also mark the beginning of a new era of a personalized approach to asthma treatment. The realization that asthma is a very heterogeneous disease is highly reflected in the rich assortment of these targeted therapies in the late-stage pipeline.

Highlights

Key Questions Answered

• Asthma symptoms can be controlled in the majority of patients using the current standard therapies. Nevertheless, in around 5-10% of people with asthma, the disease remains symptomatic and inadequately controlled. Therefore, there are considerably high unmet needs within the indication. What are the main unmet needs in this market? Will the drugs under development fulfil the unmet needs of the asthma market?
• The current late-stage asthma pipeline is dominated by biologics that target various inflammatory pathways in specific patient subpopulations. Will the late-stage drugs make a significant impact on the asthma market? What strategies are drug developers undertaking to penetrate this difficult but potentially very lucrative market?
• The prevalence of environmental diseases, including asthma, is increasing worldwide, with an estimated 400 million people likely to suffer from asthma in 2025. How will epidemiological changes impact the growth of the future market?

Key Findings

• The main driver of the enormous expansion of the asthma market will be the uptake of novel targeted biologic agents and once-daily ICS and ICS/LABA therapies in the next-generation inhalers.
• The major global barrier for the asthma market will be the generic erosion of the leading brands for asthma treatment, such as Advair (fluticasone propionate/salmeterol)and Symbicort (budesonide/formoterol fumarate).
• Companies are trying to penetrate or dominate the asthma market using two main approaches: 1) developing drugs with different delivery devices to capitalize on long-established off-patent therapies; 2) introducing biologics, in particular, interleukin inhibitors, to treat severe uncontrolled asthma.
• The largest unmet needs mainly reflect the high level of heterogeneity of the disease, the lack of patient compliance with the standard therapies, and the high cost of medications for asthma treatment. In addition, there is a lack of diagnostic tools to provide a reliable diagnosis of asthma in young children.

Scope

• Overview of asthma, including epidemiology, etiology, pathophysiology, symptoms, diagnosis, and treatment guidelines.
• Annualized asthma therapeutics market revenue, annual cost of therapy and treatment usage pattern data from 2013 and forecast for ten years to 2023.
• Key topics covered include strategic competitor assessment, market characterization, unmet needs, clinical trial mapping and implications for the asthma therapeutics market.
• Pipeline analysis: comprehensive data split across different phases, emerging novel trends under development, and detailed analysis of late-stage pipeline drugs.
• Analysis of the current and future market competition in the global asthma therapeutics market. Insightful review of the key industry drivers, restraints and challenges. Each trend is independently researched to provide qualitative analysis of its implications.

Reasons to buy

• Develop and design your in-licensing and out-licensing strategies through a review of pipeline products and technologies, and by identifying the companies with the most robust pipeline. Additionally a list of acquisition targets included in the pipeline product company list.
• Develop business strategies by understanding the trends shaping and driving the global asthma therapeutics market.
• Drive revenues by understanding the key trends, innovative products and technologies, market segments, and companies likely to impact the global asthma therapeutics market in future.
• Formulate effective sales and marketing strategies by understanding the competitive landscape and by analysing the performance of various competitors.
• Identify emerging players with potentially strong product portfolios and create effective counter-strategies to gain a competitive advantage.
• Track drug sales in the global asthma therapeutics market from 2013-2023.
• Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments and strategic partnerships.

Table of Contents

1 Table of Contents 9
1.1 List of Tables 16
1.2 List of Figures 24

2 Introduction 25
2.1 Catalyst 25
2.2 Related Reports 25
2.3 Upcoming Related Reports 25

3 Disease Overview 26
3.1 Etiology and Pathophysiology 26
3.1.1 Etiology 26
3.1.2 Pathophysiology 28
3.1.3 Prognosis 30
3.1.4 Quality of Life 30
3.2 Symptoms 31

4 Epidemiology 32
4.1 Disease Background 32
4.2 Risk Factors and Comorbidities 33
4.2.1 A family history of asthma is a strong predictor for asthma in children and adults 34
4.2.2 Puberty alters the risk for asthma in boys and girls 35
4.2.3 Maternal smoking during pregnancy greatly increases the risk of childhood asthma 36
4.2.4 Allergens are well-known asthma triggers 37
4.2.5 Common workplace exposures account for up to 11% of asthma cases in adults 38
4.2.6 Urban living conditions, not race, increase the risk of asthma by almost 50% 39
4.2.7 Obesity almost triples the risk of developing asthma 40
4.2.8 Asthmatics are 90% more likely to develop GERD 41
4.2.9 85% of asthmatics have allergic rhinitis 42
4.2.10 Panic disorders are common in asthmatics and severely impact disease control 43
4.2.11 39% of asthmatics are likely to develop depression 44
4.3 Global Trends 44
4.3.1 US 45
4.3.2 France 47
4.3.3 Germany 48
4.3.4 Italy 49
4.3.5 Spain 49
4.3.6 UK 50
4.3.7 Japan 52
4.3.8 Australia 52
4.3.9 China 53
4.3.10 India 54
4.4 Forecast Methodology 55
4.4.1 Sources Used 56
4.4.2 Forecast Assumptions and Methods 69
4.4.3 Sources Not Used 76
4.5 Epidemiology Forecast for Asthma (2013-2023) 77
4.5.1 Lifetime Prevalent Cases of Asthma 77
4.5.2 Age-Specific Lifetime Prevalent Cases of Asthma 79
4.5.3 Sex-Specific Lifetime Prevalent Cases of Asthma 82
4.5.4 Age-Standardized Lifetime Prevalence of Asthma 84
4.5.5 Distribution of Lifetime Prevalent Cases of Asthma by Severity 86
4.6 Discussion 88
4.6.1 Conclusions on Epidemiology Trends 88
4.6.2 Limitations of the Analysis 90
4.6.3 Strengths of the Analysis 91

5 Disease Management 93
5.1 Diagnosis and Treatment Overview 93
5.1.1 Diagnosis 93
5.1.2 Treatment Guidelines, Clinical Practice, and Leading Prescribed Drugs 94
5.1.3 Clinical Practice 96
5.2 US 101
5.3 France 103
5.4 Germany 105
5.5 Spain 107
5.6 Italy 109
5.7 UK 111
5.8 Japan 113
5.9 Australia 114

6 Competitive Assessment 116
6.1 Overview 116
6.2 Strategic Competitor Assessment 118
6.3 Inhaled Corticosteroids 122
6.3.1 Flovent (fluticasone propionate) 122
6.3.2 Pulmicort (budenoside) 127
6.3.3 Other Inhaled Corticosteroids 132
6.4 Long-Acting Beta-Agonists 133
6.4.1 Overview 133
6.5 Inhaled Corticosteroids/Long-Acting Beta-Agonists 134
6.5.1 Advair (fluticasone propionate/salmeterol xinafoate) 134
6.5.2 Symbicort (budenoside/formoterol fumarate) 141
6.5.3 Breo Ellipta (fluticasone furoate/vilanterol trifenatate) 146
6.5.4 Dulera (mometasone furoate/formoterol fumarate) 150
6.5.5 Flutiform (fluticasone propionate/formoterol fumarate) 154
6.5.6 Fostair (beclomethasone dipropionate/formoterol fumarate) 158
6.6 Leukotriene Modifiers 163
6.6.1 Singulair (montelukast) 163
6.6.2 Other Leukotriene Modifiers 168
6.7 Short-Acting Beta-Agonists 168
6.7.1 Overview 168
6.7.2 Efficacy 170
6.7.3 Safety 171
6.8 Targeted Therapies 172
6.8.1 Xolair (omalizumab) 172
6.9 Anticholinergics 176
6.9.1 Spiriva (tiotropium bromide) 176

7 Unmet Need and Opportunity 182
7.1 Overview 182
7.2 Personalized Therapies to Control Severe Asthma 183
7.2.1 Unmet Need 183
7.2.2 Gap Analysis 184
7.2.3 Opportunity 184
7.3 Better Patient Compliance 184
7.3.1 Unmet Need 184
7.3.2 Gap Analysis 185
7.3.3 Opportunity 186
7.4 Lower Cost of Asthma Medications 186
7.4.1 Unmet Need 186
7.4.2 Gap Analysis 187
7.4.3 Opportunity 187
7.5 Proper Diagnosis of Asthma in Children 187
7.5.1 Unmet Need 187
7.5.2 Gap Analysis 188
7.5.3 Opportunity 188

8 Pipeline Assessment 189
8.1 Overview 189
8.2 Clinical Trial Mapping 191
8.2.1 Clinical Trials by Country 191
8.2.2 Clinical Trials by Phase and Trial Status 192
8.3 Promising Drugs in Clinical Development 194
8.3.1 Fluticasone furoate 195
8.3.2 Cinquil (reslizumab) 200
8.3.3 Bosatria (mepolizumab) 205
8.3.4 Lebrikizumab 211
8.3.5 Benralizumab 217
8.3.6 Dupilumab 222
8.3.7 Quilizumab 229
8.3.8 Tralokinumab 234

9 Current and Future Players 240
9.1 Overview 240
9.2 Trends in Corporate Strategy 242
9.3 Company Profiles 244
9.3.1 GlaxoSmithKline 244
9.3.2 Merck & Co. 247
9.3.3 AstraZeneca/MedImmune 250
9.3.4 Novartis 252
9.3.5 Roche/Genentech 255
9.3.6 Teva 257
9.3.7 Boehringer Ingelheim 260

10 Market Outlook 263
10.1 Global Markets 263
10.1.1 Forecast 263
10.1.2 Drivers and Barriers - Global Issues 269
10.2 United States 271
10.2.1 Forecast 271
10.2.2 Key Events 276
10.2.3 Drivers and Barriers 277
10.3 France 279
10.3.1 Forecast 279
10.3.2 Key Events 284
10.3.3 Drivers and Barriers 284
10.4 Germany 287
10.4.1 Forecast 287
10.4.2 Key Events 292
10.4.3 Drivers and Barriers 293
10.5 Italy 295
10.5.1 Forecast 295
10.5.2 Key Events 300
10.5.3 Drivers and Barriers 300
10.6 Spain 302
10.6.1 Forecast 302
10.6.2 Key Events 308
10.6.3 Drivers and Barriers 309
10.7 United Kingdom 311
10.7.1 Forecast 311
10.7.2 Key Events 316
10.7.3 Drivers and Barriers 316
10.8 Japan 318
10.8.1 Forecast 318
10.8.2 Key Events 323
10.8.3 Drivers and Barriers 323
10.9 Australia 325
10.9.1 Forecast 325
10.9.2 Key Events 330
10.9.3 Drivers and Barriers 330

11 Appendix 332
11.1 Bibliography 332
11.2 Abbreviations 357
11.3 Methodology 362
11.4 Forecasting Methodology 362
11.4.1 Diagnosed Asthma Patients 363
11.4.2 Percent Drug-Treated Patients 363
11.4.3 Drugs Included in Each Therapeutic Class 363
11.4.4 Key Launch and Patent Expiry Dates 364
11.4.5 General Pricing Assumptions 365
11.4.6 Individual Drug Assumptions 366
11.4.7 Generic Erosion 374
11.4.8 Pricing of Pipeline Agents 374
11.5 Physicians and Specialists Included in This Study 376
11.6 About the Authors 379
11.6.1 Author 379
11.6.2 Author/Reviewer 379
11.6.3 Reviewer 380
11.6.4 Epidemiologist 380
11.6.5 Global Head of Healthcare 381
11.7 About GlobalData 382
11.8 Disclaimer 382

List of Tables

Table 1: Symptoms of Asthma 31
Table 2: GINA Guidelines for Classification of Asthma by Severity 33
Table 3: Risk Factors and Comorbidities of Asthma 34
Table 4: Lifetime Prevalence (%) of Asthma by Race in the US, All Ages, Both Sexes, 2001-2011 46
Table 5: Trends in the Prevalence (%) of Self-Reported Asthma in Children in Spain 50
Table 6: Trends in the Lifetime Prevalence (%) of Asthma in the UK 51
Table 7: Lifetime Prevalence (%) of Asthma in Children in China 54
Table 8: Prevalence (%) of Asthma in Children and Adults in India 55
Table 9: Questions Asked to Assess Lifetime Asthma Prevalence 56
Table 10: 10MM, Epidemiological Sources of Lifetime Asthma Prevalence Data 57
Table 11: 10MM, Epidemiological Sources of Asthma Severity Data 58
Table 12: Overview of the Ellis Criteria for Childhood Asthma Severity Classification 68
Table 13: 10MM, Lifetime Prevalent Cases of Asthma, All Ages, Men and Women, N (Millions), 2013-2023 78
Table 14: 10MM, Lifetime Prevalent Cases of Asthma, by Age, N (Millions), (Row %), 2013 81
Table 15: All Markets, Lifetime Prevalent Cases of Asthma, by Sex, All Ages, N (Row %), 2013 83
Table 16: 10MM, Lifetime Prevalent Cases of Asthma by Severity, All Ages, Men and Women, N (Row %), 2013 87
Table 17: Treatment Guidelines for Asthma by Country 94
Table 18: Most Prescribed Drugs for Asthma by Class and Disease Severity in the Global Markets, 2013 95
Table 19: Dosing of Common ICSs for Adult Asthma Therapy to Achieve Equivalent Therapeutic Potency 98
Table 20: Recommended Low Daily Dose of ICSs in Children with Asthma Under Five Years of Age 100
Table 21: Country Profile, Asthma Management - US 102
Table 22: Country Profile - Asthma Management, France 104
Table 23: Country Profile, Asthma Management - Germany 106
Table 24: Country Profile, Asthma Management - Spain 108
Table 25: Country Profile, Asthma Management - Italy 110
Table 26: Country Profile, Asthma Management - UK 112
Table 27: Country Profile, Asthma Management - Japan 114
Table 28: Country Profile, Asthma Management - Australia 115
Table 29: Leading Treatments for Asthma, 2014 121
Table 30: Product Profile - Flovent 123
Table 31: Efficacy - Flovent Diskus Versus Placebo 124
Table 32: Adverse Events Related to Flovent Diskus 125
Table 33: Flovent SWOT Analysis, 2014 125
Table 34: Global Sales Forecast ($) for Flovent, 2013-2023 126
Table 35: Product Profile - Pulmicort 128
Table 36: Pulmicort-Associated Adverse Events 130
Table 37: Pulmicort SWOT Analysis, 2014 131
Table 38: Global Sales Forecast ($) for Pulmicort, 2013-2023 132
Table 39: Summary of Other Marketed ICSs for Asthma Treatment, 2014 133
Table 40: Product Profile - Advair 137
Table 41: Efficacy - Advair Diskus Versus Its Individual Components 138
Table 42: Advair, Frequency of Drug-Related Adverse Events 139
Table 43: Advair SWOT Analysis, 2014 139
Table 44: Global Sales Forecast ($) for Advair, 2013-2023 141
Table 45: Product Profile - Symbicort 142
Table 46: Efficacy - Symbicort Versus Its Individual Components 143
Table 47: Symbicort, Frequency of Drug-Related Adverse Events 144
Table 48: Symbicort SWOT Analysis, 2014 144
Table 49: Global Sales Forecast ($) for Symbicort, 2013-2023 146
Table 50: Product Profile - Breo Ellipta 147
Table 51: Efficacy - Breo Ellipta Versus Flovent 148
Table 52: Safety - Breo Ellipta Versus Flovent 148
Table 53: Breo Ellipta SWOT Analysis, 2014 149
Table 54: Global Sales Forecast ($) for Breo Ellipta, 2013-2023 150
Table 55: Product Profile - Dulera 151
Table 56: Efficacy - Dulera Versus Its Individual Components 152
Table 57: Dulera - Frequency of Drug-Related Adverse Events 152
Table 58: Dulera SWOT Analysis, 2014 153
Table 59: Global Sales Forecast ($) for Dulera, 2013-2023 154
Table 60: Product Profile - Flutiform 155
Table 61: Efficacy - Flutiform Versus Advair 156
Table 62: Safety - Flutiform Versus Advair 156
Table 63: Flutiform SWOT Analysis, 2014 157
Table 64: Global Sales Forecast ($) for Flutiform, 2013-2023 158
Table 65: Product Profile - Fostair 160
Table 66: Efficacy - Fostair Versus Symbicort 161
Table 67: Safety - Fostair Versus Symbicort 161
Table 68: Fostair SWOT Analysis, 2014 162
Table 69: Global Sales Forecast ($) for Fostair, 2013-2023 163
Table 70: Product Profile - Singulair 165
Table 71: Efficacy - Singulair+Pulmicort Versus Double-Dose of Pulmicort 166
Table 72: Safety of Singulair+Pulmicort Compared With a Double Dose of Pulmicort 166
Table 73: Singulair SWOT Analysis, 2014 167
Table 74: Global Sales Forecast ($) for Singulair, 2013-2023 168
Table 75: Overview of the Leading SABAs for Asthma Treatment, 2014 170
Table 76: Efficacy - Nebulized Levalbuterol Versus Nebulized Albuterol 171
Table 77: Adverse Events Related to Nebulized Levalbuterol and Nebulized Albuterol 171
Table 78: Product Profile - Xolair 173
Table 79: Efficacy - Xolair Versus Placebo 174
Table 80: Xolair SWOT Analysis, 2014 175
Table 81: Global Sales Forecast ($) for Xolair, 2013-2023 176
Table 82: Product Profile - Spiriva 178
Table 83: Efficacy - Spiriva's Versus LABA and Double-Dose ICS 179
Table 84: Adverse Events Related to the Use of Spiriva 179
Table 85: Spiriva SWOT Analysis, 2014 180
Table 86: Global Sales Forecast ($) for Spiriva, 2013-2023 181
Table 87: Unmet Need and Opportunity in Asthma 182
Table 88: Asthma - Clinical Trials by Phase and Status, 2014 193
Table 89: Asthma - Late Stage Pipeline, 2014 194
Table 90: Product Profile - Fluticasone Furoate 196
Table 91: Fluticasone Fuorate Efficacy Versus Placebo and Fluticasone Propionate 197
Table 92: Fluticasone Furoate Safety Profile 197
Table 93: Fluticasone Furoate SWOT Analysis, 2014 199
Table 94: Global Sales Forecast ($) for Fluticasone Furoate, 2013-2023 200
Table 95: Product Profile - Cinquil 201
Table 96: Efficacy of Cinquil Versus Placebo 202
Table 97: Cinquil's Safety Profile 202
Table 98: Cinquil SWOT Analysis, 2014 204
Table 99: Global Sales Forecast ($) for Cinquil, 2013-2023 205
Table 100: Product Profile - Bosatria 207
Table 101: Efficacy of Bosatria Versus Placebo 207
Table 102: Bosatria's Safety Profile 208
Table 103: Bosatria SWOT Analysis, 2012 210
Table 104: Global Sales Forecast ($) for Bosatria, 2013-2023 211
Table 105: Product Profile - Lebrikizumab 212
Table 106: Efficacy of Lebrikizumab Versus Placebo 213
Table 107: Lebrikizumab Safety Profile 213
Table 108: Lebrikizumab SWOT Analysis, 2014 216
Table 109: Global Sales Forecast ($) for Lebrikizumab, 2013-2023 217
Table 110: Product Profile - Benralizumab 218
Table 111: Efficacy of Benralizumab Versus Placebo 219
Table 112: Benralizumab SWOT Analysis, 2014 221
Table 113: Global Sales Forecast ($) for Benralizumab, 2013-2023 222
Table 114: Product Profile - Dupilumab 224
Table 115: Efficacy of Dupilumab Versus Placebo 225
Table 116: Dupilumab's Safety Profile 225
Table 117: Dupilumab SWOT Analysis, 2014 227
Table 118: Global Sales Forecast ($) for Dupilumab, 2013-2023 228
Table 119: Product Profile - Quilizumab 230
Table 120: Efficacy of Quilizumab Versus Placebo 230
Table 121: Quilizumab SWOT Analysis, 2014 233
Table 122: Global Sales Forecasts ($) for Quilizumab, 2013-2023 234
Table 123: Product Profile - Tralokinumab 235
Table 124: Efficacy of Tralokinumab Versus Placebo 236
Table 125: Tralokinumab's Safety Profile 236
Table 126: Tralokinumab SWOT Analysis, 2014 238
Table 127: Global Sales Forecast ($) for Tralokinumab, 2013-2023 239
Table 128: Key Companies in the Asthma Market, 2014 241
Table 129: GSK's Asthma Portfolio Assessment, 2014 246
Table 130: GSK SWOT Analysis, 2013 247
Table 131: Merck's Asthma Portfolio Assessment, 2014 249
Table 132: Merck SWOT Analysis, 2012 249
Table 133: AstraZeneca's Portfolio Assessment, 2014 251
Table 134: AstraZeneca SWOT Analysis, 2014 252
Table 135: Novartis' Asthma Portfolio Assessment, 2014 254
Table 136: Novartis SWOT Analysis, 2012 255
Table 137: Roche/Genentech's Portfolio Assessment, 2014 256
Table 138: Roche/Genentech SWOT Analysis, 2014 257
Table 139: Teva's Portfolio Assessment, 2014 259
Table 140: Teva SWOT Analysis, 2014 260
Table 141: Boehringer Ingelheim's Portfolio Assessment, 2014 262
Table 142: Boehringer Ingelheim SWOT Analysis, 2014 262
Table 143: Global Sales Forecast ($m) for Asthma, 2013-2023 265
Table 144: Global Asthma Market - Drivers and Barriers, 2014 269
Table 145: Sales Forecast ($m) for Asthma in the US 2013-2023 273
Table 146: Key Events Impacting Sales for Asthma in the US, 2013-2023 276
Table 147: Asthma Market - Drivers and Barriers in the US, 2013-2023 277
Table 148: Sales Forecast ($m) for Asthma in France, 2013-2023 281
Table 149: Key Events Impacting Sales for Asthma in France, 2013-2023 284
Table 150: French Asthma Market - Drivers and Barriers, 2013-2023 284
Table 151: Sales Forecast ($m) for Asthma in Germany, 2013-2023 289
Table 152: Key Events Impacting Sales for Asthma in Germany, 2013-2023 292
Table 153: Asthma Market - Drivers and Barriers in Germany, 2013-2023 293
Table 154: Sales Forecasts ($m) for Asthma in Italy, 2013-2023 297
Table 155: Key Events Impacting Sales for Asthma in Italy, 2013-2023 300
Table 156: Asthma Market - Drivers and Barriers in Italy, 2013-2023 300
Table 157: Sales Forecast ($m) for Asthma in Spain, 2013-2023 305
Table 158: Key Events Impacting Sales for Asthma in Spain, 2013-2023 308
Table 159: Asthma Market - Drivers and Barriers in Spain, 2013-2023 309
Table 160: Sales Forecast ($m) for Asthma in the UK, 2013-2023 313
Table 161: Key Events Impacting Sales for Asthma in the UK, 2013-2023 316
Table 162: Asthma Market - Drivers and Barriers in the UK, 2013-2023 316
Table 163: Sales Forecast ($m) for Asthma in Japan, 2013-2023 320
Table 164: Key Events Impacting Sales for Asthma in Japan, 2013-2023 323
Table 165: Asthma Market - Drivers and Barriers in Japan, 2013-2023 323
Table 166: Sales Forecast ($m) for Asthma in Australia, 2013-2023 327
Table 167: Key Events Impacting Sales for Asthma in Australia, 2013-2023 330
Table 168: Asthma Market - Drivers and Barriers in Australia, 2013-2023 330
Table 169: Key Launch Dates 364
Table 170: Key Patent Expiries 364
Table 171: High-Prescribing Physicians (non-KOLs) Surveyed, By Country 378

List of Figures

Figure 1: Lifetime Prevalence (%) of Asthma by Race in the US, All Ages, Both Sexes, 2001-2011 47
Figure 2: 10MM, Lifetime Prevalent Cases of Asthma, All Ages, Men and Women, N (Millions), 2013-2023 79
Figure 3: 10MM, Lifetime Prevalent Cases of Asthma, by Age, N (Millions), 2013 82
Figure 4: All Markets, Lifetime Prevalent Cases of Asthma, by Sex, N (Millions), 2013 84
Figure 5: 10MM, Age-Standardized Lifetime Prevalence of Asthma, All Ages, Men and Women, %, 2013 85
Figure 6: 10MM, Lifetime Prevalent Cases of Asthma by Severity, All Ages, Men and Women, N (Millions), 2013 88
Figure 7:Stepwise Disease Management Approach for Asthma in Adults 97
Figure 8: Stepwise Disease Management Approach for Asthma in Children Age Five and Younger 99
Figure 9: Asthma Therapeutics - Clinical Trials by Country, 2014 192
Figure 10: Competitive Assessment of Late-Stage Pipeline Agents in Asthma, 2013-2023 195
Figure 11: Company Portfolio Gap Analysis in Asthma, 2013-2023 242
Figure 12: Global Sales for Asthma by Region, 2013-2023 268
Figure 13: Sales for Asthma in the US by Drug Class, 2013-2023 275
Figure 14: Sales for Asthma in France by Drug Class, 2013-2023 283
Figure 15: Sales for Asthma in Germany by Drug Class, 2013-2023 291
Figure 16: Sales for Asthma in Italy by Drug Class, 2013-2023 299
Figure 17: Sales for Asthma in Spain by Drug Class, 2013-2023 307
Figure 18: Sales for Asthma in the United Kingdom by Drug Class, 2013-2023 315
Figure 19: Sales for Asthma in Japan by Drug Class, 2013-2023 322
Figure 20: Sales for Asthma in Australia by Drug Class, 2013-2023 329